辰欣药业 Cisen Pharmaceutical   
辰欣药业股份有限公司是一家综合性化学药品制剂生产企业。公司现为国家级高新技术企业、博士后科研工作站、山东省泰山学者药学特聘专家设岗单位、山东省企业技术中心、山东省抗生素工程技术研究中心，获得国家发改委产业化扶持基金、国家科技部科技型企业技术创新基金、中国专利山东明星企业等荣誉。2011年5月，“辰欣”商标被国家工商总局认定为“中国驰名商标”，同时入选2011中国医药研发产品线最佳工业企业及2011年中国医药工业最具投资价值企业。
　　公司秉承“推陈出新、诚实守信”的企业理念，坚持以科技为先导，以质量求生存，以创新求发展，走出了一条科技创新之路，先后投资建成了开发区第一工业园十五个生产车间和现代化的动物实验楼及大型高架立体仓库。2010年6月辰欣第二工业园隆重奠基，加速了辰欣药业向工艺难度大、生命周期长、附加值高的新产品进军的步伐。公司可生产大输液（非 PVC 软袋输液、塑料瓶输液、玻璃瓶输液）、水针、冻干粉针、片剂、膏剂、滴眼剂、胶囊剂和小原料药等八大剂型近 400个规格的产品。其中，输液被评为山东省名牌产品，输液产品产量位居国内单厂第一，水针产量居山东省第一位。
　　辰欣药业以保障和提高病患者生命健康质量为己任，致力于自主研发、生产能够填补国内空白的药品。每年将销售收入的6%用于科技研发投入，先后与中国药科大学、沈阳药科大学、山东大学、山东省医科院、山东省医药工业研究所、中科院药物研究所、军事医学科学院等科研院所建立了长期合作关系，成功走出了一条“产、学、研联合创新”的路子，建立了从市场调研、开发设计到试制生产的一条龙开发体系，形成了研制一代、储备一代、生产一代的良性循环。 新产品涵盖了心脑血管类、抗菌、抗病毒类、抗癌类等多门类100多个品种。其中，由辰欣药业自主研制的阿德福韦酯（原料及片剂）被评为国家一类新药证书，获得山东省科技进步一等奖，并获得国家科技部、省、市科技创新基金扶持。该药物的研制成功是我国在自主研发乙肝药物治疗领域取得的重大突破，对于推动我国医药产业的技术进步，加快我国医药高技术成果产业化，提高我国生物医药产业技术创新能力和国际竞争力具有重要意义，也将是辰欣品牌再次提升的发动机。
　　辰欣药业非常重视产品的质量管理工作。我们坚持“质量第一，预防为主”的质量管理方针，秉承“药因质盛，业以牌荣”的质量管理理念，建立了一整套缜密有效的质量保证体系，总经理对产品质量全面负责，公司质量保证部向各车间派驻质量员，对车间生产质量管理工作进行监督指导，使质量否决权落到实处。各车间在生产岗位设置工艺监控点，严把质量检验监督关。目前，公司所有剂型的产品全部通过了国家食品药品监督管理局认证中心 GMP 认证和三体系认证，并被山东省企业联合会评定为山东省质量管理和现场管理样板单位。
　　十二五期间，辰欣药业将继续以科技创新为首要工作，通过引进战略投资者、上市、合资、增资等多种形式进行融资，增加新产品研发投入，提高新产品技术含量，努力实现2015年销售收入100亿元，利税20亿元的宏伟目标，为中国医药事业的发展做出更大的贡献！

Cisen Pharmaceutical Co., Ltd. is a comprehensive chemical pharmaceutical enterprise. The company has developed into a national hi-tech enterprise, which owns a Post-Doctoral Research workstation, Shandong Taishan scholar posts for Specially Hired specialist on medicines, center of enterprise technology of Shandong and antibiotics engineering technology research center of Shandong, obtains National Development and Reform Committee Industrialization support funds, Shandong Star Enterprise of Chinese Patent etc. The logo of Cisen has been appraised as China famous trademark by SAIC, meanwhile, the company has been selected as the best industrial enterprise of R&D product line of China's Pharmaceutical and enterprise with the best investment value of China's pharmaceutical industry in 2011. Cisen is committed to “Innovation and Integrity”, which is considered as a core value of Cisen. Cisen always adheres to the science and technology as the guide, survive by quality, develop by innovation, forming a path of technological innovation. The company has successively invested and built the first Cisen industrial park, 15 production workshops, and elevated 3-dimensional storehouse. Cisen second industrial park held its grand groundbreaking ceremony on 19 June 2010. The construction of Cisen second industrial park quicken its pace of producing new products with difficult technology, long life cycle, intensive capital and high added value. The company can produce infusion solution(non PVC soft bag infusions, plastic bottle infusions, glass bottle infusions), injection, lyophilized powder injections, tablets, ointments, eye drops, capsules and API etc, 8 series nearly 400 varieties products. Among which, the infusion solution products have been appraised by Shandong province as a famous brand, the single factory capacity of infusion solution ranks No.1 in China and the capacity ranks No.1 in Shandong province. Cisen Pharmaceutical Co., Ltd regards safeguard and promotion for health quality of patients as its own duty and devotes to independently develop and produce drugs to fill the domestic void. Cisen spends 6% of annual sales revenue in its technology research. Cisen has established a strategic relationships with the Pharmaceutical University, Shenyang Pharmaceutical University, Shandong University, Shandong Academy of Medical Sciences, Shandong Institute of pharmaceutical Industry, Institute of Pharmacology under Chinese Sciences, Academy of Military Medical Sciences and other domestic colleges; the company has developed a joint innovation system of “Industry-study-research”. Cisen has established a coordinated process of “Market research-Development and design-Trial production ”and has formed a virtuous cycle of “Develop-Reserve-Production”. New drugs include many category of and more than 100 drugs, such as cardiovascular type, antibacterial, antiviral, anticancer, and so on. Particularly, the anti-HBV Adefovir Dipivoxil Tablets(APIs and tablet) that the company has developed obtains the certificate of State First-Class Innovative Drug, the first prize of technological advancement of Shandong and technological innovation support fund from municipal government, provincial government and Ministry of Science and Technology. The successful development of this drug is a major breakthrough of independent development in the field of HBV drug treatment in China, what has a great significance in promoting technology advancement of China's pharmaceutical industry, quickening the industrialization of China's hi-tech achievements, improving the technology innovation ability of China's pharmaceutical industry and international competitiveness. It will become the engine for promoting the brand value of Cisen as well.